The TEEL Study: A Phase I Trial of Tamoxifen With Ribociclib (LEE011) in Adult Patients With Advanced ER+ (HER2 Negative) Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Goserelin (Primary) ; Ribociclib (Primary) ; Tamoxifen (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- Acronyms TEEL
- 16 May 2017 Status changed from suspended to active, no longer recruiting.
- 27 Dec 2016 Status changed from recruiting to suspended.
- 15 Feb 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.